Business Description
Aileron Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US00887A1051
Description
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 250.88 | |||||
Equity-to-Asset | 0.45 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 34.3 | |||||
3-Year EPS without NRI Growth Rate | 35.7 | |||||
3-Year FCF Growth Rate | 28.4 | |||||
3-Year Book Growth Rate | -36.7 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 17.02 | |||||
9-Day RSI | 20.92 | |||||
14-Day RSI | 25.44 | |||||
6-1 Month Momentum % | 2.56 | |||||
12-1 Month Momentum % | 78.77 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.82 | |||||
Quick Ratio | 2.82 | |||||
Cash Ratio | 2.66 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -30.7 | |||||
Shareholder Yield % | 0.03 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -100.48 | |||||
ROA % | -36.25 | |||||
ROIC % | -52.77 | |||||
ROC (Joel Greenblatt) % | -64013.79 | |||||
ROCE % | -39.57 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.04 | |||||
EV-to-EBIT | -2.23 | |||||
EV-to-EBITDA | -2.25 | |||||
EV-to-FCF | -2.12 | |||||
Earnings Yield (Greenblatt) % | -44.84 | |||||
FCF Yield % | -34.26 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALRN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aileron Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -3.22 | ||
Beta | 1.93 | ||
Volatility % | 121.99 | ||
14-Day RSI | 25.44 | ||
14-Day ATR ($) | 0.233624 | ||
20-Day SMA ($) | 3.0905 | ||
12-1 Month Momentum % | 78.77 | ||
52-Week Range ($) | 1.01 - 7.42 | ||
Shares Outstanding (Mil) | 21.59 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Aileron Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Aileron Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Aileron Therapeutics Inc Frequently Asked Questions
What is Aileron Therapeutics Inc(ALRN)'s stock price today?
The current price of ALRN is $2.76. The 52 week high of ALRN is $7.42 and 52 week low is $1.01.
When is next earnings date of Aileron Therapeutics Inc(ALRN)?
The next earnings date of Aileron Therapeutics Inc(ALRN) is 2024-08-09 Est..
Does Aileron Therapeutics Inc(ALRN) pay dividends? If so, how much?
Aileron Therapeutics Inc(ALRN) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |